RNS HEARD - Selected Publications

1. An allelic cluster of DQ∈restriction fragments is associated with multiple sclerosis: evidence that a second haplotype may influence disease susceptibility. Heard RNS, Cullen C, Middleton D, Hawkins SA, Hern JEC, McDonald WI, Batchelor JR, Lechler RI. Human Immunology 25:111, 1989.

2. HLA and Autoimmunity. Heard RNS. In HLA and Disease, Lechler RI ed, pp. 119-147. Academic Press, London, 1994.

3. The CCR5 deletion mutation fails to protect against multiple sclerosis. Bennetts BH, Teutsch SM, Buhler MM, Heard RNS, and Stewart GJ. Human Immunology, 58:52-59, 1997.

4. Lack of restriction of T cell receptor beta-gene usage in cerebrospinal fluid (CSF) lymphocytes in acute optic neuritis. Heard, RNS, Teutsch SM, Bennetts BH, Lee S, Deane E, and Stewart GJ. Journal of Neurology, Neurosurgery and Psychiatry 67:585-590, 1999.

5. Hyperbaric oxygen therapy for multiple sclerosis (Protocol for a Cochrane Review). Bennett M, Heard R. In: The Cochrane Library, Issue 1, 2001. Oxford: Update Software

6. Hyperbaric oxygen therapy for multiple sclerosis. Bennett M, Heard R. Cochrane Database Syst Rev. 2004;(1):CD003057

7. Identification of eleven novel and common single nucleotide polymorphisms in the interleukin-7 receptor gene and their associations with multiple sclerosis. Teutsch SM, Booth DR, Bennetts, BH, Heard RNS, Stewart GJ. (2003) Eur J Hum Genet 11:509-515

8. A high density screen for linkage in multiple sclerosis. The International Multiple Sclerosis Genetics Consortium. (2005). Am. J. Hum. Gen. 77(3):454-67

9. CD127 immunophenotyping suggests altered CD4+ T cell regulation in primary progressive multiple sclerosis. McKay FC, Swain LI, Schibechi SD, Rubio JP, Kilpatrick TJ, Heard RN, Stewart GJ, Booth DR. J Autoimmunity 2008 Aug: 31(1):52-8.

10. Refining genetic associations in multiple sclerosis. International Multiple Sclerosis Genetics Consortium (IMSGC). Lancet Neurol. 2008 Jul; 7(7):567-9

11. Genome-wide scan identifies novel multiple sclerosis susceptibility loci on chromosomes 12 and 20. ANZgene Consortium. Nature Genetics 2009 Jul;41(7):824-8 Epub 2009 Jun 14

12. Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis. Booth DR, Heard RN, Stewart GJ, Cox M, Scott RJ, Lechner-Scott J, Goris A, Dobosi R, Dubois B, Saarela J, Leppä V, Peltonen L, Pirttila T, Cournu-Rebeix I, Fontaine B, Bergamaschi L, D'Alfonso S, Leone M, Lorentzen AR, Harbo HF, Celius EG, Spurkland A, Link J, Kockum I, Olsson T, Hillert J, Ban M, Baker A, Kemppinen A, Sawcer S, Compston A, Robertson NP, De Jager PL, Hafler DA, Barcellos LF, Ivinson AJ, McCauley JL, Pericak-Vance MA, Oksenberg JR, Hauser SL, Sexton D, Haines J, International Multiple Sclerosis Genetics Consortium (IMSGC). Nat Genet. 2010 Jun;42(6):469-70

13. Functionally significant differences in expression of disease-associated IL-7 receptor alpha haplotypes in CD4 T cells and dendritic cells. Hoe E, McKay FC, Schibeci SD, Gandhi K, Heard RN, Stewart GJ, Booth DR. J Immunol. 2010 Mar 1;184(5):2512-7. Epub 2010 Jan 22

14. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium. Nature. 2011 Aug 10;476(7359):214-9

15. Molecular inconsistencies in a Fragile X male with early onset ataxia. Hwang YT, Dudding T, Aliaga SM, Arpone M, Francis D, Li X, Slater HR, Rogers C, Bretherton L, du Sart D, Heard R*, Godler DE*. Genes (Basel). 2016 Sep 21;7(9) (*joint last authors)

16. Partially methylated alleles, microdeletion, and tissue mosaicism in a Fragile X male with tremor and ataxia at 30 years of age. Hwang YT, Aliaga SM, Arpone M, Francis D, Li X, Chong B, Slater HR, Rogers C,

Bretherton L, Hunter M, Heard R*, Godler DE*. Am J Med Genet A. 2016 Dec;170(12):3327-3332 (*joint last authors)

Other publications by year

1978

17. Plasma protein binding of maprotyline: influence of a-1 acid glycoprotein. Braithwaite R, Heard R, Snape A. Proc.Br.Pharm.Soc. 25:23-24, 1978.

18. An enthusiast's view of the NHS. Heard R. Rostrum 86:16-18, 1978.

1982

19. Student elective in Papua New Guinea (letter). Heard R. Br Med J 285:1504, 1982.

1988

20. The detection of HLA Class II restriction fragment length polymorphisms in multiple sclerosis using pooled DNA samples.Heard RNS, Dodi IA, Batchelor JR, McDonald WI, Lechler RI. International Congress, Virology and Immunology in Multiple Sclerosis. Edited by L.Cazullo, Berlin:Springer-Verlag, 1988.

21. An HLA-DQa allele associated with multiple sclerosis: evidence for the involvement of two haplotypes in disease susceptibility. Heard RNS, Batchelor JR, McDonald WI, Lechler RI. J.Neurol. 235(supp):S7, 1988.

1989

22. An RFLP study of HLA-D gene polymorphism in multiple sclerosis. Heard RNS, McDonald WI, Batchelor JR, Lechler RI. In Histocompatibility Testing 1988: Report of the 10th International Histocompatibility Workshop. New York: Springer Verlag, 1989.

23. A study of HLA-DR2 and multiple sclerosis using alloreactive T cell clones. Man S, Sharrock CEM, Heard RNS, Lechler RI, Batchelor JR. In Histocompatibility Testing 1988: Report of the 10th International Histocompatibility Workshop. New York: Springer Verlag, 1989.

1991

24. Studies on the molecular immunogenetics of Class II histocompatibility antigens in multiple sclerosis. Heard RNS. MD Thesis, University of London, 1991.

1993

25. New horizons in the treatment of multiple sclerosis. Heard RNS. Medical Journal of Australia 158(10):714-716, 1993.

26. HTLV-1 in Australia. Heard RNS. Medical Journal of Australia 159(1):3-4, 1993.

127. Brainstem serotonergic neurones in chronic alcoholics with and without the memory impairment of Korsakoff's psychosis. Halliday G, Ellis J, Heard R, Caine D, Harper C. Journal of Neuropathology and Experimental Neurology 52(6):567-579, 1993

1995

28. TAP2 polymorphisms in Australian multiple sclerosis patients. Bennetts BH, Teutsch SM, Dunckley H, Heard RNS and Stewart GJ. Journal of Neuroimmunology, 59:113-121 1995

1996

29. HLA-DQA1 and DQB1 genotyping by PCR-RFLP heteroduplex and homoduplex analysis. Teutsch SM, Bennetts BH, Castle M, Hibbins M, Heard RNS and Stewart GJ. European Journal of Immunology 23:107-120. 1996

1997

30. HLA-DR, -DQA1 and –DQB1 associations in Australian multiple sclerosis patients. Stewart GJ, Teutsch SM, Castle M, Heard RNS and Bennetts BH. European Journal of Immunogenetics, 24:81-92, 1997.

1999

31. The DRB1Val86/Val86 genotype associates with multiple sclerosis in Australian patients. Teutsch SM, Bennetts, BH, Buhler MM, Heard RNS, Stewart GJ. Hum Immunology 60:715-722, 1999.

32. HLA-DMB gene and HLA-DRA promoter region polymorphisms in Australian multiple sclerosis patients. Bennetts BH, Teutsch SM, Buhler MM, Heard RNS, Stewart GJ. Hum Immunology 60:886-893, 1999.

33. Angiotropic large cell lymphoma mimicking multiple sclerosis associated transverse myelitis. Ormsby A, Prayson RA, Heard R. Journal of Clinical Neuroscience, 6(5):408-410, 1999

2000

34. Evaluation of the Apo-1/Fas promoter Mva I polymorphism in multiple sclerosis. Teutsch SM*, Huang QR*, Buhler MM, Bennetts BH, Heard RNS, Manolios N, Stewart GJ. (2000) Multiple Sclerosis 6:14-18 (* joint first authors)

35. T cell receptor ß chain genotyping in Australian relapsing-remitting multiple sclerosis patients. Buhler MMcW, Bennetts BH, Heard RNS, Stewart GJ. (2000) Multiple Sclerosis. Jun;6(3):140-7

36. Creutzfeldt-Jakob disease: the need for vigilance. Cohn DA, Crimmins DS, Heard R, Rose M. J Clin Neurosci. 2000 Jul;7(4):277-9.

2001

37. Severe anterograde amnesia with extensive hippocampal degeneration in a case of rapidly progressive frontotemporal dementia. Caine D, Patterson K, Hodges JR, Heard R, Halliday G. Neurocase. 2001;7(1):57-64.

38. Treatment of multiple sclerosis with hyperbaric oxygen therapy. Bennett M, Heard R. (2001). Undersea Hyperb Med. 28(3):117-22.

2002

39. A genome screen for linkage in Australian sibling-pairs with multiple sclerosis. Genes and Immunity Ban, M, Stewart GJ, Bennetts BH, Heard R, Simmons R, Maranian, M, Compston A, Sawcer SJ. (2002) 3:464-469.

2003

40. FDG-PET in paraneoplastic neuropathy. Wilkinson MD, Fulham MJ, Heard RN, McCaughan BC, McCarthy SW. (2003). Neurology 60(10):1668.

41. A genome-wide screen for linkage disequilibrium in Australian HLA-DRB1*1501 positive multiple sclerosis patients. Ban M, Sawcer SJ, Heard RN, Bennetts BH, Adams S, Booth D, Perich V, Setakis E, Compston A, Stewart GJ. (2003). J Neuroimmunol.143(1-2):60-4.

42. A meta-analysis of whole genome linkage screens in multiple sclerosis. GAMES and the Transatlantic Multiple Sclerosis Genetics Cooperative (2003) Journal of Neuroimmunology, 143:39-46.

2004

43. Association of common T cell activation gene polymorphisms with multiple sclerosis in Australian patients. Teutsch SM, Booth DR, Bennetts BH, Heard RN, Stewart GJ. (2004). J Neuroimmunol. 148(1-2):218-30.

2005

44. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of

primary progressive multiple sclerosis. Booth DR, Arthur AT, Teutsch SM, Bye C, Rubio JP, Armati PJ, Pollard JP, Heard RNS, Stewart GJ. (2005). J. Mol. Med. 83(10):822-30

45. An investigation of NOS2A promoter polymorphisms in Australian multiple sclerosis patients. Bugeja MJ, Booth DR, Bennetts BH, Heard RNS, Burgner D, Stewart GJ. (2005).Eur. J. Hum. Genet. 13:815-822.

2006

46. Analysis of neutralising antibodies to therapeutic interferon beta in MS patients: a comparison of three methods in a large Australian cohort. McKay F, Schibeci S, Heard R, Stewart G, Booth D. (2006). J. Immunol. Methods. 310(1-20)20-9.

47. An investigation of polymorphisms in the 17q11.2-12 CC chemokine gene cluster for association with MS in Australians. Bugeja MJ, Booth DR, Bennetts BH, Heard RNS, Rubio J, Stewart GS. (2006). BMC Medical Genetics, 7:64 (BioMed Central online publication)

48. An investigation of polymorphisms in the 4q13.3-21.1 CXC chemokine cluster for association with MS in Australians. Bugeja MJ, Booth DR, Bennetts BH, Heard RNS, Stewart GS. (2006). Mult Scler. 12(6):710-22

49. Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. The GAMES Collaborative Group, Ban M, Booth D, Heard R et al. J Neuroimmunol 2006 Oct;179(1-2):108-16.

50. An investigation of polymorphisms in the 4q1 3.3-21.1 CXC chemokine gene cluster for association with multiple sclerosis in Australians. Bugeja MJ, Booth DR, Bennetts BH, Heard RN, Stewart GJ. (2006). Multiple Sclerosis 12(6):710-22..

2007

51. The spectrum of multiple sclerosis. Heard R. Current Allergy Asthma Reports. 2007. 7(4):280-4.

52. Haplotypes of the interleukin 7 receptor alpha gene are correlated with altered expression in whole blood cells in multiple sclerosis. McKay FC, Swain LI, Schibeci SD, Rubio JP, Kilpatrick TJ, Heard RN, Stewart GJ, Booth DR. (2007). Genes and Immunity 9(1): 1-6.

53. SNP mapping and candidate gene sequencing in the class I region of the HLA complex: searching for multiple sclerosis susceptibility genes in Tasmanians. Burfoot RK, Jensen CJ, Field J, Stankovich J, Varney MD, Johnson LJ, Butzkueven H, Booth D, Bahlo M, Tait BD, Taylor BV, Speed TP, Heard R, Stewart GJ, Foote SJ, Kilpatrick TJ, Rubio JP. Tissue Antigens. 2008 Jan;71(1):42-50. Epub 2007 Oct 30.

54. Familial effects on the clinical course of multiple sclerosis. Hensiek AE, Seaman SR, Barcellos LF, Oturai A, Eraksoi M, Cocco E, Vecsei L, Stewart G, Dubois B, Bellman-Strobl J, Leone M, Andersen O, Bencsik K, Booth D, Celius EG, Harbo HF, Hauser SL, Heard R, Hillert J, Myhr KM, Marrosu MG, Oksenberg JR, Rajda C, Sawcer SJ, Sørensen PS, Zipp F, Compston DA. Neurology. 2007 Jan 30;68(5):376-83.

2008

55. SNP mapping and candidate gene sequencing in the class I region of the HLA complex: searching for multiple sclerosis susceptibility genes in Tasmanians. Burfoot RK, Jensen CJ, Field J, Stankovich J, Varney MD, Johnson LJ, Butzkueven H, Booth D, Bahlo M, Tait BD, Taylor BV, Speed TP, Heard R, Stewart GJ, Foote SJ, Kilpatrick TJ, Rubio JP. Tissue Antigens. 2008 Jan;71(1):42-50. Epub 2007 Oct 30

56. BAFF is a biological response marker to IFNb treatment in multiple sclerosis. Gandhi K, McKay FC, Arthur J, Heard RN, Stewart GJ, Booth DR. (2008). J Interferon Cytokine Res. 28(9):529-39

57. Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission. Arthur AT, Armati PJ, Bye C, Southern MS Genetics Consortium, Heard RN, Stewart GJ, Pollard JD, Booth DR. Med Genet. 2008 Mar 19:9:17.

58. Sylvian aqueduct syndrome with slit ventricles and over-drainage in shunted adult hydrocephalus due to aqueduct stenosis. Maroulis H, Halmagyi MG, Heard R, Cook R. (2007). J Neurosurgery 109(5):939-43.

59. BAFF is a biological response marker to IFN-beta treatment in multiple sclerosis. Gandhi KS, McKay FC,

Schibeci SD, Arthur JW, Heard RN, Stewart GJ, Booth DR. J Interferon Cytokine Res. 2008 Sep;28(9):529-39.

2009

60. The expanding genetic overlap between multiple sclerosis and type 1 diabetes. The International Multiple Sclerosis Genetics Consortium (IMSGC), Ban M, Booth DR, Heard RN et al. Genes and Immunity 2009. 10(1):11-4

61. HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. Stankovich J, Butzkueven H, Marritt M et al. Tissue Antigens 2009 74(1):17-21

62. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Harung HP, Kappos L, Jeffery D, Comi G. Lancet Neurol. 2009 Oct;8(10):889-97. Epub 2009 Sep 2.

63. HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis. Stankovich J, Butzkueven H, Marriott M, Chapman C, Tubridy N, Tait BD, Varney MD, Taylor BV, Foote SJ; ANZgene Consortium, Kilpatrick TJ, Rubio JP. Tissue Antigens. 2009 Jul;74(1):17-21. Epub 2009 Apr 21.

64. Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Ban M, Goris A, Lorentzen AR, Baker A, Mihalova T, Ingram G, Booth DR, Heard RN, Stewart GJ, Bogaert E, Dubois B, Harbo HF, Celius EG, Spurkland A, Strange R, Hawkins C, Robertson NP, Dudbridge F, Wason J, De Jager PL, Hafler D, Rioux JD, Ivinson AJ, McCauley JL, Pericak-Vance M, Oksenberg JR, Hauser SL, Sexton D, Haines J, Sawcer S; Wellcome Trust Case-Control Consortium (WTCCC), Compston A. Eur J Hum Genet. 2009 Oct;17(10):1309-13. Epub 2009 Mar 18.

65. The expanding genetic overlap between multiple sclerosis and type I diabetes. International Multiple Sclerosis Genetics Consortium (IMSGC). Genes Immun. 2009 Jan;10(1):11-4. Epub 2008 Nov 6.

2010

66. Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis. Gandhi KS, McKay FC, Diefenbach E, Crossett B, Schibeci SD, Heard RN, Stewart GJ, Booth DR, Arthur JW. PLoS One. 2010 May 5;5(5):e10484.

67. Hyperbaric oxygen therapy for multiple sclerosis. Bennett M, Heard R. CNS Neurosci Ther. 2010 Apr;16(2):115-24.

68. Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients. Jensen CJ, Stankovich J, Van der Walt A, Bahlo M, Taylor BV, van der Mei IA, Foote SJ, Kilpatrick TJ, Johnson LJ, Wilkins E, Field J, Danoy P, Brown MA; Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), Rubio JP, Butzkueven H. PLoS One. 2010 Apr 2;5(4):e10003.

69. The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Gandhi KS, McKay FC, Cox M, Riveros C, Armstrong N, Heard RN, Vucic S, Williams DW, Stankovich J, Brown M, Danoy P, Stewart GJ, Broadley S, Moscato P, Lechner-Scott J, Scott RJ, Booth DR; ANZgene Multiple Sclerosis Genetics Consortium. Hum Mol Genet. 2010 Jun 1;19(11):2134-43. Epub 2010 Feb 27.

70. Interleukin 7 receptor alpha chain haplotypes vary in their influence on multiple sclerosis susceptibility and response to interferon Beta. Hoe E, McKay F, Schibeci S, Heard R, Stewart G, Booth D. J Interferon Cytokine Res. 2010 May;30(5):291-8.

71. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group. N Engl J Med. 2010 Feb 4;362(5):402-15. Epub 2010 Jan 20.

72. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. N Engl J Med. 2010 Feb 4;362(5):387-401. Epub 2010 Jan 20.

73. A transcription factor map as revealed by a genome-wide geneexpression analysis of whole-blood mRNA transcriptome in multiple sclerosis. Riveros C, Mellor D, Gandhi KS, McKay FC, Cox MB, Berretta R, Vaezpour SY, Inostroza-Ponta M, Broadley SA, Heard RN, Vucic S, Stewart GJ, Williams DW, Scott RJ, Lechner-Scott J, Booth DR, Moscato P; ANZgene Multiple Sclerosis Genetics Consortium. PloS One. 2010 Dec 1;5(12):e14176.

74. A polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple sclerosis. Field J, Browning SR, Johnson LJ, Danoy P, Varney MD, Tait BD, Gandhi KS, Charlesworth JC, Heard RN; Australia and New Zealand Multiple Sclerosis Genetics Consortium, Stewart GJ, Kilpatrick TJ, Foote SJ, Bahlo M, Butzkueven H, Wiley J, Booth DR, Taylor BV, Brown MA, Rubio JP, Stankovich J. PLoS One. 2010 Oct 26;5(10):e13454.

75. MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood. Cox MB, Cairns MJ, Gandhi KS, Carroll AP, Moscovis S, Stewart GJ, Broadley S, Scott RJ, Booth DR, Lechner-Scott J; ANZgene Multiple Sclerosis GeneticsConsortium. PLoS One. 2010 Aug 11;5(8):e12132.

76. IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci. International Multiple Sclerosis Genetics Conssortium (IMSGC). Genes Immun. 2010 Jul;11(5):397-405. Epub 2010 Jun 17.

77. Novel approaches to detect serum biomarkers for clinical response to interferon-beta treatment in multiple sclerosis. Gandhi KS, McKay FC, Diefenbach E, Crossett B, Schibeci SD, Heard RN, Stewart GJ, Booth DR, Arthur JW.PLoS One. 2010 May 5;5(5):e10484.

78. Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients. Jensen CJ, Stankovich J, Van der Walt A, Bahlo M, Taylor BV, van der Mei IA, Foote SJ, Kilpatrick TJ, Johnson LJ, Wilkins E, Field J, Danoy P, Brown MA;
Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene),
Rubio JP, Butzkueven H.PLoS One. 2010 Apr 2;5(4):e10003.

79. The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Gandhi KS, McKay FC, Cox M, Riveros C, Armstrong N, Heard RN, Vucic S, Williams DW, Stankovich J, Brown M, Danoy P, Stewart GJ, Broadley S, Moscato P, Lechner-Scott J, Scott RJ, Booth DR; ANZgene Multiple Sclerosis Genetics
Consortium.Hum Mol Genet. 2010 Jun 1;19(11):2134-43. Epub 2010 Feb 27.

80. Interleukin 7 receptor alpha chain haplotypes vary in their influence on multiple sclerosis susceptibility and response to interferon Beta. Hoe E, McKay F, Schibeci S, Heard R, Stewart G, Booth D. J Interferon Cytokine Res. 2010 May;30(5):291-8.

81. Functionally significant differences in expression of disease-associated IL-7
receptor alpha haplotypes in CD4 T cells and dendritic cells. Hoe E, McKay FC, Schibeci SD, Gandhi K, Heard RN, Stewart GJ, Booth DR. J Immunol. 2010 Mar 1;184(5):2512-7. Epub 2010 Jan 22.

82. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J,Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S,Aradhye S, Kappos L; TRANSFORMS Study Group.N Engl J Med. 2010 Feb 4;362(5):402-15. Epub 2010 Jan 20.

83. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group. N Engl J Med. 2010 Feb 4;362(5):387-401. Epub 2010 Jan 20.

2011

84. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X,

Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group.Lancet Neurol. 2011 Jun;10(6):520-9. Epub 2011 May 13.

85. Comparing genotyping algorithms for Illumina's Infinium whole-genome SNP BeadChips. Irizarry RA.Ritchie ME, Liu R, Carvalho BS; Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene). BMC Bioinformatics. 2011 Mar 8;12:68.

86. Polymorphisms in the receptor tyrosine kinase MERTK gene are associated with multiple sclerosis susceptibility. Ma GZ, Stankovich J; Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), Kilpatrick TJ, Binder MD, Field J.PLoS One. 2011 Feb 8;6(2):e16964.

87. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.
Patsopoulos NA; Bayer Pharma MS Genetics Working Group; Steering Committees of Studies Evaluating IFNβ-1b and a CCR1-Antagonist; ANZgene Consortium; GeneMSA; International Multiple Sclerosis Genetics Consortium, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J, Sandbrink R, Pohl C, Edan G, Kappos L, Miller D, Montalbán J, Polman CH, Freedman MS, Hartung HP, Arnason BG, Comi G, Cook S, Filippi M, Goodin DS, Jeffery D, O'Connor P, Ebers GC, Langdon D, Reder AT, Traboulsee A, Zipp F, Schimrigk S, Hillert J, Bahlo M, Booth DR, Broadley S, Brown MA, Browning BL, Browning SR, Butzkueven H, Carroll WM, Chapman C, Foote SJ, Griffiths L, Kermode AG, Kilpatrick TJ, Lechner-Scott J, Marriott M, Mason D, Moscato P, Heard RN, Pender MP, Perreau VM, Perera D, Rubio JP, Scott RJ, Slee M, Stankovich J, Stewart GJ, Taylor BV, Tubridy N, Willoughby E, Wiley J, Matthews P, Boneschi FM, Compston A, Haines J, Hauser SL, McCauley J, Ivinson A, Oksenberg JR, Pericak-Vance M, Sawcer SJ, De Jager PL, Hafler DA, de Bakker PI. Ann Neurol. 2011 Dec;70(6):897-912

2012

88. Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects. Lill CM, Liu T, Schjeide BM, Roehr JT, Akkad DA, Damotte V, Alcina A, Ortiz MA, Arroyo R, Lopez de Lapuente A, Blaschke P, Winkelmann A, Gerdes LA, Luessi F, Fernadez O, Izquierdo G, Antigüedad A, Hoffjan S, Cournu-Rebeix I, Gromöller S, Faber H, Liebsch M, Meissner E, Chanvillard C, Touze E, Pico F, Corcia P; ANZgene Consortium,{dagger}, Dörner T, Steinhagen-Thiessen E, Baeckman L, Heekeren HR, Li SC, Lindenberger U, Chan A, Hartung HP, Aktas O, Lohse P, Kümpfel T, Kubisch C, Epplen JT, Zettl UK, Fontaine B, Vandenbroeck K, Matesanz F, Urcelay E, Bertram L, Zipp F. J Med Genet. 2012 Sep;49(9):558-62

89. Interleukin-6 gene promoter-572 C allele may play a role in rate of disease progression in multiple sclerosis. Yan J, Liu J, Lin CY, Anzgene AN, Csurhes PA, Pender MP, McCombe PA, Greer JM. Int J Mol Sci. 2012 Oct 22;13(10):13667-79.

90. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group.
Lancet Neurol. 2012 May;11(5):420-8.

91. Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis. Radue EW, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, Zhang-Auberson L, Francis G, Burtin P, Kappos L; FTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study Group. Arch Neurol. 2012 Oct;69(10):1259-69.

2013

92. Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis. Lee SH, Harold D, Nyholt DR; ANZGene Consortium; International Endogene Consortium; Genetic and Environmental Risk for Alzheimer's disease Consortium, Goddard ME, Zondervan KT, Williams J, Montgomery GW, Wray NR, Visscher PM.
Hum Mol Genet. 2013 Feb 15;22(4):832-41.

93. Identity-by-descent mapping to detect rare variants conferring susceptibility to multiple sclerosis.
Lin R, Charlesworth J, Stankovich J, Perreau VM, Brown MA; ANZgene Consortium, Taylor BV.
PLoS One. 2013;8(3):e56379

94. Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. Patsopoulos NA, Barcellos LF, Hintzen RQ, Schaefer C, van Duijn CM, Noble JA, Raj T; IMSGC; ANZgene, Gourraud PA, Stranger BE, Oksenberg J, Olsson T, Taylor BV, Sawcer S, Hafler DA, Carrington M, De Jager PL, de Bakker PI.
PLoS Genet. 2013 Nov;9(11):e1003926

95. A "candidate-interactome" aggregate analysis of genome-wide association data in multiple sclerosis. Mechelli R, Umeton R, Policano C, Annibali V, Coarelli G, Ricigliano VA, Vittori D, Fornasiero A, Buscarinu MC; International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium,2, Romano S, Salvetti M, Ristori G.
PLoS One. 2013 May 16;8(5):e63300

2014

96. Can lower risk patients presenting with transient ischaemic attack be safely managed as outpatients? Griffiths D, Sturm J, Heard R, Reyneke E, Whyte S, Clarke T, O'Brien W, Crimmins D.
J Clin Neurosci. 2014 Jan;21(1):47-50

97. No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis. Goris A, van Setten J, Diekstra F, Ripke S, Patsopoulos NA, Sawcer SJ; International Multiple Sclerosis Genetics Consortium, van Es M; Australia and New Zealand MS Genetics Consortium, Andersen PM, Melki J, Meininger V, Hardiman O, Landers JE, Brown RH Jr, Shatunov A, Leigh N, Al-Chalabi A, Shaw CE, Traynor BJ, Chiò A, Restagno G, Mora G, Ophoff RA, Oksenberg JR, Van Damme P, Compston A, Robberecht W, Dubois B, van den Berg LH, De Jager PL, Veldink JH, de Bakker PI.
Hum Mol Genet. 2014 Apr 1;23(7):1916-22

98. Progressive neuropsychiatric symptoms and motor impairment.
Ghadiri M, Buckland ME, Sutton IJ, Al Jahdhami S, Flanagan S, Heard R, Barnett Y, Brennan J, Barnett MH.
JAMA Neurol. 2014 Jun;71(6):794-8

99. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies.
Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E.
J Clin Neurosci. 2014 Jun 30. pii: S0967-5868(14)00180-5

100. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy.
Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E.
J Clin Neurosci. 2014 Jun 28. pii: S0967-5868(14)00184-2

101. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations.
Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E.
J Clin Neurosci. 2014 Jun 30. pii: S0967-5868(14)00183-0

2015

102. A new era in the treatment of multiple sclerosis. Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies JM, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E. Med J Aust 2015. 203(3) 139-141.

2016

103. Multifocal neuropathy presenting as pseudodystonia. Garg N, Heard RNS, Kiers L, Gerraty R, Yiannikas C. Movement Disorders - Clinical Practice. 2016. DOI: 10.1002/mdc3.12336

2017

104. Incidence and prevalence of NMOSD in Australia and New Zealand.Bukhari W, Prain KM, Waters P et al. J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26